Corvus aims to provide growth capital for proven assets and businesses, closing the gap between venture capital and PE houses specialised in buyout transactions. These include growth oriented opportunities, entrepreneurially driven companies, proven reserves and resources and established business models. Sector experience includes Energy, Commodities, Minerals, Specialist Financials, Insurance, Media, Technology & Health Care.
Our Strategy is to target assets or companies which we believe have significant inherent value which is not otherwise being achieved on behalf of shareholders. Working with partners with the appropriate skill sets and financial resources, we aim to invest in companies that can demonstrate the ability to produce strong income generation or have a proven or anticipated stable and cash-generating business. Typical deal situations include farm-in opportunities, expansion financing, management and shareholder buyouts and pre-IPO funding.
Corvus is the founding and majority shareholder of Manoira Corporation, a specialty animal treatment company focused on developing proprietary intellectual property using solid form technology. Manoira specialise in the research and development of pharmaceutical and other health products for livestock and pets and intend to develop their portfolio of products to prevent and treat a variety of animal diseases and conditions.
Corvus is the founding and majority shareholder of Conduit Pharmaceuticals, a disease agnostic life science company providing an efficient model for compound development. Conduit successfully completed a business combination with Murphy Canyon Acquisition Corp. in September 2023 for a proforma enterprise value of approximately $720 MM.
Corvus Capital is pleased to have advised Taylor Partners, the activist shareholder of East Imperial plc (LON: EISB), alongside Strand Hanson, on Taylor Partner's successful proposition to make a number of Board changes at EISB.
Corvus is the founding shareholder of Ebers Tech Inc., a private Canadian pharmaceutical company that utilises Co-crystallization and other technology to generate and monetize unique patented compounds and Intellectual Property around cannabinoids and psychedelics.